Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Guanfacine hydrochloride extended release is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of …